Abstract
The diabetes pandemic demands solutions for proper glycemic control and prevention of future chronic complications that could result in organ failure or comorbidities. In this regard, we now know that patients diagnosed with diabetes require individual management plans. Thus, new treatment management strategies have been designed to allow clinicians to tailor the most appropriate therapy for diabetes patients individually. These treatment management plans extend beyond defining the appropriate medications for patients; they provide a directive toward some acute and chronic complications that should be screened for, as they are historically known to occur with diabetes. Observing any of the complications or comorbidities requires the patient medication regimen to be adapted accordingly. This chapter describes such modern treatment plans for the two primary forms of diabetes, type 1 and type 2, based on both basic and clinical studies, later incorporated in various diabetes management guidelines and outlines expected future trends.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
ADA (2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32(Suppl 1):S62–S67. https://doi.org/10.2337/dc09-S062
ADA (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33(Suppl 1):S62–SS9. https://doi.org/10.2337/dc10-S062
ADA (2018) Standards of medical care in diabetes—2018 abridged for primary care providers. Clin Diabetes 36(1):14–37. https://doi.org/10.2337/cd17-0119
Aguayo-Mazzucato C, Bonner-Weir S (2010) Stem cell therapy for type 1 diabetes mellitus. Nat Rev Endocrinol 6(3):139–148. https://doi.org/10.1038/nrendo.2009.274
Al-Goblan AS, Al-Alfi MA, Khan MZ (2014) Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes 7:587–591. https://doi.org/10.2147/DMSO.S67400
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ et al (2019) 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 74(10):e177–e232. https://doi.org/10.1016/j.jacc.2019.03.010
Atkinson MA, Eisenbarth GS, Michels AW (2014) Type 1 diabetes. Lancet 383(9911):69–82. https://doi.org/10.1016/s0140-6736(13)60591-7
Bahman F, Greish K, Taurin S (2019) Nanotechnology in insulin delivery for management of diabetes. Pharm Nanotechnol 7(2):113–128. https://doi.org/10.2174/2211738507666190321110721
Banting FG, Best CH (1990) Pancreatic extracts. 1922. J Lab Clin Med 115(2):254–272
Beck RW, Riddlesworth TD, Ruedy KJ, Kollman C, Ahmann AJ, Bergenstal RM et al (2017) Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 5(9):700–708. https://doi.org/10.1016/s2213-8587(17)30217-6
Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30(6):586–623. https://doi.org/10.1210/er.2008-0047
Biester T, Kordonouri O, Danne T (2017) Pharmacological properties of faster-acting insulin aspart. Curr Diab Rep 17(11):101. https://doi.org/10.1007/s11892-017-0931-y
Borg DJ, Weigelt M, Wilhelm C, Gerlach M, Bickle M, Speier S et al (2014) Mesenchymal stromal cells improve transplanted islet survival and islet function in a syngeneic mouse model. Diabetologia 57(3):522–531. https://doi.org/10.1007/s00125-013-3109-4
Bottino R, Knoll MF, Knoll CA, Bertera S, Trucco MM (2018) The future of islet transplantation is now. Front Med 5:202. https://doi.org/10.3389/fmed.2018.00202
Boughton CK, Hovorka R (2019) Is an artificial pancreas (closed-loop system) for type 1 diabetes effective? Diabet Med 36(3):279–286. https://doi.org/10.1111/dme.13816
Butterfield WJ, Camp JL, Hardwick C, Holling HE (1957) Clinical studies on the hypoglycaemic action of the sulphonylureas. Lancet 272(6972):753–756
Castle JR, DeVries JH, Kovatchev B (2017) Future of automated insulin delivery systems. Diabetes Technol Ther 19(Suppl 3):S-67–S-72. https://doi.org/10.1089/dia.2017.0012
Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW et al (2018) IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281. https://doi.org/10.1016/j.diabres.2018.02.023
Cierpka-Kmiec K, Wronska A, Kmiec Z (2019) In vitro generation of pancreatic beta-cells for diabetes treatment. I. Beta-like cells derived from human pluripotent stem cells. Folia Histochem Cytobiol 57(1):1–14. https://doi.org/10.5603/FHC.a2019.0001
Corradi-Perini C, Santos TM, Camara NOS, Riella MC, Aita CAM (2017) Co-transplantation of xenogeneic bone marrow–derived Mesenchymal stem cells alleviates rejection of pancreatic islets in non-obese diabetic mice. Transplant Proc 49(4):902–905. https://doi.org/10.1016/j.transproceed.2017.01.064
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G et al (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61(12):2461–2498. https://doi.org/10.1007/s00125-018-4729-5
de Souza BM, Boucas AP, Oliveira FD, Reis KP, Ziegelmann P, Bauer AC et al (2017) Effect of co-culture of mesenchymal stem/stromal cells with pancreatic islets on viability and function outcomes: a systematic review and meta-analysis. Islets 9(2):30–42. https://doi.org/10.1080/19382014.2017.1286434
Deacon CF (2019) Physiology and pharmacology of DPP-4 in glucose homeostasis and the treatment of type 2 diabetes. Front Endocrinol 10:80. https://doi.org/10.3389/fendo.2019.00080
Evans M, Schumm-Draeger PM, Vora J, King AB (2011) A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab 13(8):677–684. https://doi.org/10.1111/j.1463-1326.2011.01395.x
Fatima N, Faisal SM, Zubair S, Ajmal M, Siddiqui SS, Moin S et al (2016) Role of pro-inflammatory cytokines and biochemical markers in the pathogenesis of type 1 diabetes: correlation with age and glycemic condition in diabetic human subjects. PLoS One 11(8):e0161548. https://doi.org/10.1371/journal.pone.0161548
Fink H, Herbert C, Gilor C (2018) Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. Domest Anim Endocrinol 64:17–30. https://doi.org/10.1016/j.domaniend.2018.03.007
Fonte P, Araujo F, Reis S, Sarmento B (2013) Oral insulin delivery: how far are we? J Diabetes Sci Technol 7(2):520–531. https://doi.org/10.1177/193229681300700228
Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93(1):137–188. https://doi.org/10.1152/physrev.00045.2011
Forouhi NG, Wareham NJ (2014) Epidemiology of diabetes. Medicine (Abingdon) 42(12):698–702. https://doi.org/10.1016/j.mpmed.2014.09.007
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation 139(22):2516–2527. https://doi.org/10.1161/circulationaha.119.039996
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al (2019) Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary. Endocr Pract 25(1):69–100. https://doi.org/10.4158/cs-2018-0535
Girard J (2017) Glucagon, a key factor in the pathophysiology of type 2 diabetes. Biochimie 143(12):33–36. https://doi.org/10.1016/j.biochi.2017.10.004
Grant RW, Kirkman MS (2015) Trends in the evidence level for the American Diabetes Association’s “standards of medical care in diabetes” from 2005 to 2014. Diabetes Care 38(1):6–8. https://doi.org/10.2337/dc14-2142
Gruessner AC (2011) 2011 Update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the international pancreas transplant registry (IPTR). Rev Diabet Stud 8(1):6–16. https://doi.org/10.1900/rds.2011.8.6
Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS et al (2015) American association of clinical endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract 21(Suppl 1):1–87. https://doi.org/10.4158/ep15672.gl
Harsch IA, Kaestner RH, Konturek PC (2018) Hypoglycemic side effects of sulfonylureas and repaglinide in ageing patients - knowledge and self-management. J Physiol Pharmacol 69(4). https://doi.org/10.26402/jpp.2018.4.15
Heinemann L, Parkin CG (2018) Rethinking the viability and utility of inhaled insulin in clinical practice. J Diabetes Res 2018:4568903. https://doi.org/10.1155/2018/4568903
Heinemann L, Fritz I, Khatami H, Edelman SV (2017) Administration of biosimilar insulin analogs: role of devices. Diabetes Technol Ther 19(2):79–84. https://doi.org/10.1089/dia.2016.0263
Heller S, White D, Lee E, Lawton J, Pollard D, Waugh N et al (2017) A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE trial. Health Technol Assess 21(20):1–278. https://doi.org/10.3310/hta21200
Hieronymus L, Griffin S (2015) Role of amylin in type 1 and type 2 diabetes. Diabetes Educ 41(1 Suppl):47s–56s. https://doi.org/10.1177/0145721715607642
Ikegami H, Noso S, Babaya N, Kawabata Y (2011) Genetics and pathogenesis of type 1 diabetes: prospects for prevention and intervention. J Diabetes Investig 2(6):415–420. https://doi.org/10.1111/j.2040-1124.2011.00176.x
Jovanovic A, Sudar-Milovanovic E, Obradovic M, Pitt SJ, Stewart AJ, Zafirovic S et al (2017) Influence of a high-fat diet on cardiac iNOS in female rats. Curr Vasc Pharmacol 15(5):491–500
Jung HS, Kim MJ, Hong SH, Lee YJ, Kang S, Lee H et al (2014) The potential of endothelial colony-forming cells to improve early graft loss after intraportal islet transplantation. Cell Transplant 23(3):273–283. https://doi.org/10.3727/096368912x661364
Kalra S, Gupta Y (2015) Sulfonylureas. JPMA 65(1):101–104
Kalra K, Chandrabose ST, Ramasamy TS, Kasim N (2018) Advances in the generation of functional beta-cells from induced pluripotent stem cells as a cure for diabetes mellitus. Curr Drug Targets 19(13):1463–1477. https://doi.org/10.2174/1389450119666180605112917
Katsarou A, Gudbjornsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ et al (2017) Type 1 diabetes mellitus. Nat Rev Dis Primers 3:17016. https://doi.org/10.1038/nrdp.2017.16
Kerby A, Jones ES, Jones PM, King AJ (2013) Co-transplantation of islets with mesenchymal stem cells in microcapsules demonstrates graft outcome can be improved in an isolated-graft model of islet transplantation in mice. Cytotherapy 15(2):192–200. https://doi.org/10.1016/j.jcyt.2012.10.018
Krall LP, White P, Bradley RF (1958) Clinical use of the biguanides and their role in stabilizing juvenile-type diabetes. Diabetes 7(6):468–477
Kullmann S, Veit R, Peter A, Pohmann R, Scheffler K, Haring HU et al (2018) Dose-dependent effects of intranasal insulin on resting-state brain activity. J Clin Endocrinol Metab 103(1):253–262. https://doi.org/10.1210/jc.2017-01976
Kunisada Y, Tsubooka-Yamazoe N, Shoji M, Hosoya M (2012) Small molecules induce efficient differentiation into insulin-producing cells from human induced pluripotent stem cells. Stem Cell Res 8(2):274–284. https://doi.org/10.1016/j.scr.2011.10.002
Ledet G, Graves RA, Bostanian LA, Mandal TK (2015) A second-generation inhaled insulin for diabetes mellitus. Am J Health Syst Pharm 72(14):1181–1187. https://doi.org/10.2146/ajhp140540
Leon BM, Maddox TM (2015) Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes 6(13):1246–1258. https://doi.org/10.4239/wjd.v6.i13.1246
Liu Z, Ma S (2017) Recent advances in synthetic alpha-Glucosidase inhibitors. Chem Med Chem 12(11):819–829. https://doi.org/10.1002/cmdc.201700216
Livingstone R, Boyle JG, Petrie JR (2017) A new perspective on metformin therapy in type 1 diabetes. Diabetologia 60(9):1594–1600. https://doi.org/10.1007/s00125-017-4364-6
Lopez Vicchi F, Luque GM, Brie B, Nogueira JP, Garcia Tornadu I, Becu-Villalobos D (2016) Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res 109:74–80. https://doi.org/10.1016/j.phrs.2015.12.029
Lupsa BC, Inzucchi SE (2018) Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 61(10):2118–2125. https://doi.org/10.1007/s00125-018-4663-6
Maclean H (1926) Some observations on diabetes and insulin in general practice. Postgrad Med J 1(6):73–77
Mastrandrea LD (2010) Inhaled insulin: overview of a novel route of insulin administration. Vasc Health Risk Manag 6:47–58
McGuire H, Longson D, Adler A, Farmer A, Lewin I (2016) Management of type 2 diabetes in adults: summary of updated NICE guidance. BMJ 353:i1575. https://doi.org/10.1136/bmj.i1575
McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME et al (2019) Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA. Circulation 139(3):351–361. https://doi.org/10.1161/circulationaha.118.038352
Mehtala J, Khanfir H, Bennett D, Ye Y, Korhonen P, Hoti F (2019) Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. Diabetol Int 10(1):24–36. https://doi.org/10.1007/s13340-018-0360-4
Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC (2005) Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration ? Diabetologia 48(11):2221–2228
Nair M (2007) Diabetes mellitus, part 1: physiology and complications. Br J Nurs 16(3):184–188. https://doi.org/10.12968/bjon.2007.16.3.22974
Nakamura T, Fujikura J, Anazawa T, Ito R, Ogura M, Okajima H et al (2019) Long-term outcome of islet transplantation on insulin-dependent diabetes mellitus: an observational cohort study. J Diabetes Investig. https://doi.org/10.1111/jdi.13128
National Clinical Guideline Centre (2015) Type 1 diabetes in adults: diagnosis and management. London: National Institute for Health and Care Excellence (UK)
Naziruddin B, Iwahashi S, Kanak MA, Takita M, Itoh T, Levy MF (2014) Evidence for instant blood-mediated inflammatory reaction in clinical autologous islet transplantation. Am J Transplant 14(2):428–437. https://doi.org/10.1111/ajt.12558
Obradovic M, Sudar E, Zafirovic S, Stanimirovic J, Labudovic-Borovic M, Isenovic ER (2015) Estradiol in vivo induces changes in cardiomyocytes size in obese rats. Angiology 66(1):25–35. https://doi.org/10.1177/0003319713514477
Obradovic M, Stanimirovic J, Panic A, Bogdanovic N, Sudar-Milovanovic E, Cenic-Milosevic D et al (2017) Regulation of Na+/K+-ATPase by estradiol and IGF-1 in cardio-metabolic diseases. Curr Pharm Des 23(10):1551–1561
Obradovic M, Zafirovic S, Soskic S, Stanimirovic J, Trpkovic A, Jevremovic D et al (2019) Effects of IGF-1 on the cardiovascular system. Curr Pharm Des. https://doi.org/10.2174/1381612825666191106091507
Ooi CP, Loke SC (2014) Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review. Diabet Med 31(1):2–14. https://doi.org/10.1111/dme.12295
Pathak V, Pathak NM, O’Neill CL, Guduric-Fuchs J, Medina RJ (2019) Therapies for type 1 diabetes: current scenario and future perspectives. Clin Med Insights Endocrinol Diabetes 12:1179551419844521. https://doi.org/10.1177/1179551419844521
Peng Q, Zhang ZR, Gong T, Chen GQ, Sun X (2012) A rapid-acting, long-acting insulin formulation based on a phospholipid complex loaded PHBHHx nanoparticles. Biomaterials 33(5):1583–1588. https://doi.org/10.1016/j.biomaterials.2011.10.072
Pickup JC (2019) Insulin Pumps. Diabet Technol Therap 21(S1):S32–s41. https://doi.org/10.1089/dia.2019.2503
Potter KJ, Westwell-Roper CY, Klimek-Abercrombie AM, Warnock GL, Verchere CB (2014) Death and dysfunction of transplanted beta-cells: lessons learned from type 2 diabetes? Diabetes 63(1):12–19. https://doi.org/10.2337/db12-0364
Rai VK, Mishra N, Agrawal AK, Jain S, Yadav NP (2016) Novel drug delivery system: an immense hope for diabetics. Drug Deliv 23(7):2371–2390
REPOSE Study Group (2017) Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ 356. https://doi.org/10.1136/bmj.j1285
Roglic G (2016) WHO global report on diabetes: a summary. Int J Noncommun Dis 1(1):3–8
Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S (2017) Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag 20(1):6–12. https://doi.org/10.1089/pop.2015.0181
Rys PM, Ludwig-Slomczynska AH, Cyganek K, Malecki MT (2018) Continuous subcutaneous insulin infusion vs multiple daily injections in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials and observational studies. Eur J Endocrinol 178(5):545–563. https://doi.org/10.1530/eje-17-0804
Sanchez-Rangel E, Inzucchi SE (2017) Metformin: clinical use in type 2 diabetes. Diabetologia 60(9):1586–1593. https://doi.org/10.1007/s00125-017-4336-x
Schmid V, Kullmann S, Gfrorer W, Hund V, Hallschmid M, Lipp HP et al (2018) Safety of intranasal human insulin: a review. Diabetes Obes Metab 20(7):1563–1577. https://doi.org/10.1111/dom.13279
Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–1326. https://doi.org/10.1056/NEJMoa1307684
Shah RB, Patel M, Maahs DM, Shah VN (2016) Insulin delivery methods: past, present and future. Int J Pharm Investig 6(1):1–9. https://doi.org/10.4103/2230-973x.176456
Singh M, Kumar A (2018) Risks associated with SGLT2 inhibitors: an overview. Curr Drug Saf 13(2):84–91. https://doi.org/10.2174/1574886313666180226103408
Soskic SS, Dobutovic BD, Sudar EM, Obradovic MM, Nikolic DM, Djordjevic JD et al (2011) Regulation of inducible nitric oxide synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure. Open Cardiovasc Med J 5:153–163. https://doi.org/10.2174/1874192401105010153
Souto EB, Souto SB, Campos JR, Severino P, Pashirova TN, Zakharova LY, Silva AM, Durazzo A, Lucarini M, Izzo AA, Santini A (2019) Nanoparticle delivery systems in the treatment of diabetes complications. Molecules 24(23). https://doi.org/10.3390/molecules24234209
Stanekzai J, Isenovic ER, Mousa SA (2012) Treatment options for diabetes: potential role of stem cells. Diabetes Res Clin Pract 98(3):361–368. https://doi.org/10.1016/j.diabres.2012.09.010
Sudar-Milovanovic E, Jovanovic A, Misirkic-Marjanovic M, Vucicevic L, Janjetovic K, Isenovic ER (2015) Effects of intracerebroventricularly (ICV) injected ghrelin on cardiac inducible nitric oxide synthase activity/expression in obese rats. Exp Clin Endocrinol Diabetes 123(10):581–588. https://doi.org/10.1055/s-0035-1559758
Sudar-Milovanovic E, Zafirovic S, Jovanovic A, Trebaljevac J, Obradovic M, Cenic-Milosevic D et al (2017) Hormonal regulation of nitric oxide (NO) in cardio-metabolic diseases. Curr Pharm Des 23(10):1427–1434
Vegas AJ, Veiseh O, Gurtler M, Millman JR, Pagliuca FW, Bader AR et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med. 2016;22(3):306–11. doi:10.1038/nm.4030.
Wang W, Zhou X, Kwong JSW, Li L, Li Y, Sun X (2017) Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis. Sci Rep 7(1):1717. https://doi.org/10.1038/s41598-017-01965-0
Wang LC, Fang FS, Gong YP, Yang G, Li CL (2018) Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus. Medicine 97(38):e12476. https://doi.org/10.1097/md.0000000000012476
Wanner C, Marx N (2018) SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases. Diabetologia 61(10):2134–2139. https://doi.org/10.1007/s00125-018-4678-z
WHO (2018). http://www.who.int/news-room/fact-sheets/detail/diabetes. Accessed 16 Dec 2019
Wiviott SD, Raz I, Sabatine MS (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply. N Engl J Med 380(19):1881–1882. https://doi.org/10.1056/NEJMc1902837
Wong CY, Al-Salami H, Dass CR (2018) Microparticles, microcapsules and microspheres: a review of recent developments and prospects for oral delivery of insulin. Int J Pharm 537(1–2):223–244. https://doi.org/10.1016/j.ijpharm.2017.12.036
Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD et al (2012) Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med 157(5):336–347. https://doi.org/10.7326/0003-4819-157-5-201209040-00508
Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351(11):1106–1118. https://doi.org/10.1056/NEJMra041001
Zaric BL, Obradovic M, Sudar-Milovanovic E, Nedeljkovic J, Lazic V, Isenovic ER (2019) Drug delivery systems for diabetes treatment. Curr Pharm Des 25(2):166–173. https://doi.org/10.2174/1381612825666190306153838
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31–39. https://doi.org/10.1016/s0140-6736(18)32590-x
Zoungas S, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S et al (2014) Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. Diabetologia 57(12):2465–2474. https://doi.org/10.1007/s00125-014-3369-7
Acknowledgments
This work is part of the collaboration between the Laboratory of Radiobiology and Molecular Genetics, Vinca Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia, Department of Endocrinology and Diabetes, Zemun Clinical Hospital, School of Medicine, University of Belgrade, Belgrade, Serbia, and, Computational Bioscience Research Center (CBRC) at King Abdullah University of Science and Technology (KAUST). This work was funded by the Ministry of Education, Science and Technological Development of the Republic of Serbia, and has been supported by the KAUST grant OSR#4129 (awarded to E.R.I. and V.B.B.), which also supported E.R.I., M.O., and E.S.M. M.E. has been supported by the KAUST Office of Sponsored Research (OSR) Award no. FCC/1/1976-17-01, and TG by the King Abdullah University of Science and Technology (KAUST) Base Research Fund (BAS/1/1059-01-01).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Obradovic, M., Sudar-Milovanovic, E., Gluvic, Z., Gojobori, T., Essack, M., Isenovic, E.R. (2020). Diabetes and Treatments. In: Faintuch, J., Faintuch, S. (eds) Obesity and Diabetes. Springer, Cham. https://doi.org/10.1007/978-3-030-53370-0_52
Download citation
DOI: https://doi.org/10.1007/978-3-030-53370-0_52
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-53369-4
Online ISBN: 978-3-030-53370-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)